0000905148-24-000446.txt : 20240206
0000905148-24-000446.hdr.sgml : 20240206
20240206201843
ACCESSION NUMBER: 0000905148-24-000446
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240202
FILED AS OF DATE: 20240206
DATE AS OF CHANGE: 20240206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schorno Dean L
CENTRAL INDEX KEY: 0001509688
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-29889
FILM NUMBER: 24601819
MAIL ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RIGEL PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001034842
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 943248524
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 611 GATEWAY BOULEVARD, SUITE 900
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-624-1100
MAIL ADDRESS:
STREET 1: 611 GATEWAY BOULEVARD, SUITE 900
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
X0508
4
2024-02-02
0001034842
RIGEL PHARMACEUTICALS INC
RIGL
0001509688
Schorno Dean L
RIGEL PHARMACEUTICALS, INC.
611 GATEWAY BLVD, SUITE 900
SOUTH SAN FRANCISCO
CA
94080
true
EVP & Chief Financial Officer
false
Common Stock
2024-02-02
4
S
0
5601
1.1296
D
409918
D
Common Stock
2024-02-05
4
S
0
7027
1.14
D
402891
D
These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person.
The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions ranging from $1.1228 to $1.13. Upon request, the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission staff, full information regarding the shares sold at each such separate price.
/s/ Raymond Furey (Attorney-in-Fact)
2024-02-06